Geoffrey R Oxnard MD

Associate Professor, Hematology & Medical Oncology

820 Harrison Ave | (617) 638-7523
goxnard@bu.edu

Sections

Hematology & Medical Oncology

Biography

Geoffrey Oxnard is a thoracic oncologist at Dana-Farber Cancer Institute and an Associate Professor of Medicine at Harvard Medical School. The aims of Dr. Oxnard’s research are to develop clinical applications for cancer genotyping technologies to advance precision cancer care.

Dr. Oxnard has published extensively on sensitivity and resistance to EGFR kinase inhibitors in lung cancer with a focus on the clinical biology of the EGFR T790M mutation. More recently his research has focused on genomic analysis of plasma cell-free DNA as a diagnostic to assist in treatment planning, response monitoring, and cancer detection.

Dr. Oxnard received his BA in chemistry from Harvard University and his MD from the University of Chicago-Pritzker School of Medicine. He served his residency in internal medicine at Massachusetts General Hospital and completed his fellowship in medical oncology at Memorial Sloan-Kettering Cancer Center, joining the Dana-Farber faculty in 2011.

Websites

BU Profile

Harvard Medical School Profile

Twitter

Brigham and Women's Profile

Practice Update Profile

ResearchGate

Google Scholar

Education

Medicine, MD, University of Chicago

Chemistry, AB, Harvard University

Publications

Published on 2/21/2025

Gautschi O, Park K, Solomon BJ, Tomasini P, Loong HH, De Braud F, Goto K, Peterson P, Barker S, Liming K, Oxnard GR, Frimodt-Moller B, Drilon A. Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancer: Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II Trial. J Clin Oncol. 2025 Feb 21; JCO2402076. PMID: 39983053.

PubMed

Published on 2/6/2025

Gandara DR, Agarwal N, Gupta S, Klempner SJ, Andrews MC, Mahipal A, Subbiah V, Eskander RN, Carbone DP, Riess JW, Sammons S, Snider J, Bouzit L, Cho-Phan C, Price M, Li G, Quintanilha JCF, Huang RSP, Ross JS, Fabrizio D, Oxnard GR, Graf RP. Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types. J Immunother Cancer. 2025 Feb 06; 13(2). PMID: 39915003.

PubMed

Published on 1/31/2025

Paweletz CP, Urvalek A, Ha M, Garg K, Bence Lin A, Szpurka AM, Sireci A, Oxnard GR, Janne PA. Round-robin comparison of RET rearrangement detection in ctDNA: A novel method for limited clinical samples. Clin Cancer Res. 2025 Jan 31. PMID: 39887260.

PubMed

Published on 8/5/2024

Mack PC, Keller-Evans RB, Li G, Lofgren KT, Schrock AB, Trabucco SE, Allen JM, Tolba K, Oxnard GR, Huang RSP. Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling Assay for Detecting Targetable Fusions in Nonsquamous NSCLC. Oncologist. 2024 Aug 05; 29(8):e984-e996. PMID: 38401173.

PubMed

Published on 6/3/2024

Rolfo CD, Madison RW, Pasquina LW, Brown DW, Huang Y, Hughes JD, Graf RP, Oxnard GR, Husain H. Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation. Clin Cancer Res. 2024 Jun 03; 30(11):2452-2460. PMID: 38526394.

PubMed

Published on 6/1/2024

Andrews MC, Li G, Graf RP, Fisher VA, Mitchell J, Aboosaiedi A, O'Rourke H, Shackleton M, Iddawela M, Oxnard GR, Huang RSP. Predictive Impact of Tumor Mutational Burden on Real-World Outcomes of First-Line Immune Checkpoint Inhibition in Metastatic Melanoma. JCO Precis Oncol. 2024 Jun; 8:e2300640. PMID: 38848517.

PubMed

Published on 3/1/2024

Yorio J, Lofgren KT, Lee JK, Tolba K, Oxnard GR, Schrock AB, Huang RSP, Brisbin L. Association of Timely Comprehensive Genomic Profiling With Precision Oncology Treatment Use and Patient Outcomes in Advanced Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2024 Mar; 8:e2300292. PMID: 38452312.

PubMed

Published on 2/29/2024

Mata DA, Lee JK, Shanmugam V, Marcus CB, Schrock AB, Williams EA, Ritterhouse LL, Hickman RA, Janovitz T, Patel NR, Kroger BR, Ross JS, Mirza KM, Oxnard GR, Vergilio JA, Elvin JA, Benhamida JK, Decker B, Xu ML. Liquid biopsy-based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results. Histopathology. 2024 Jun; 84(7):1224-1237. PMID: 38422618.

PubMed

Published on 2/16/2024

Kasi PM, Lee JK, Pasquina LW, Decker B, Vanden Borre P, Pavlick DC, Allen JM, Parachoniak C, Quintanilha JCF, Graf RP, Schrock AB, Oxnard GR, Lovly CM, Tukachinsky H, Subbiah V. Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types. Clin Cancer Res. 2024 Feb 16; 30(4):836-848. PMID: 38060240.

PubMed

Published on 1/1/2024

Russo A, Lee JK, Pasquina LW, Del Re M, Dilks HH, Murugesan K, Madison RW, Lee Y, Schrock AB, Comment L, Dietrich M, Oxnard GR, Rolfo C. Liquid Biopsy of Lung Cancer Before Pathological Diagnosis Is Associated With Shorter Time to Treatment. JCO Precis Oncol. 2024 Jan; 8:e2300535. PMID: 38295321.

PubMed

View full list of 205 publications.